Clinical Trial Update: SJG-136 in Treating Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer That Did Not Respond to Previous Treatment With Cisplatin or Carboplatin [Phase 2]

View source ↗

Summary

Phase 2 trial of SJG-136 in recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer that failed cisplatin/carboplatin was terminated, with re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Epithelial Cancer
• Peritoneal Cancer

Drugs mentioned

• SJG-136

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Fallopian Tube Cancer, Recurrent Ovarian Epithelial Cancer | Phase 2 | Status: TERMINATED | Results posted: 2015-05-25